Stay plugged in on news from Wisconsin’s innovation community with these recent headlines:
—Even though a decision from the U.S. Preventive Services Task Force last month improved the outlook for Madison-based Exact Sciences (NASDAQ: EXAS) and Cologuard, its stool-based DNA test for colorectal cancer, there is still disagreement about whether insurance companies will cover the test, the Wisconsin State Journalreported. Patricia Golden, a physician at Wheaton Franciscan Medical Group in Franklin, called Cologuard “an appropriate standard of care.” However, David Feldstein, a physician at the University of Wisconsin Hospital and Clinics, aka UW Health, told the newspaper that he doesn’t recommend the test, citing a lack of evidence.
—Meanwhile, the Milwaukee Journal Sentinel reported that Exact CEO Kevin Conroy was one of about 350 attendees at last week’s Cancer Moonshot Summit in Washington, D.C. Read the full story here.
;
